Maze finds new partner for Pompe drug after Sanofi deal falls through

Maze Therapeutics has secured a new partnership for its experimental Pompe disease medication, MZE001, following a previous agreement with Sanofi that was terminated due to antitrust issues. On Friday, Maze announced an agreement with Shionogi, in which Maze will receive $150 million upfront and is eligible for additional milestone payments and tiered sales royalties.

Last December, Sanofi decided not to continue with its planned license for MZE001 after the U.S. Federal Trade Commission (FTC) expressed concerns about market competition. Sanofi already offers enzyme replacement therapies for Pompe disease, including Lumizyme (alglucosidase alfa) and Nexviazyme (avalglucosidase alfa), which are administered biweekly through intravenous infusions. The original Sanofi deal could have been worth up to $750 million, with $150 million paid upfront.

Shionogi's interest in MZE001 aligns with its strategy to enhance its rare disease portfolio. Shionogi CEO Isao Teshirogi emphasized the unique and promising science behind MZE001, noting its potential as a standalone treatment or in combination with existing enzyme replacement therapies.

MZE001 is an oral inhibitor targeting GYS1, designed to limit glycogen buildup in patients suffering from Pompe disease. Data from the drug’s Phase I trial, released in February of the previous year, showed successful target engagement, leading Maze to proceed with mid-stage clinical development. Under this new arrangement, Shionogi will gain global rights to related programs and intellectual property associated with MZE001.

This partnership highlights Shionogi's commitment to expanding its presence in the rare diseases market, while offering hope for patients with Pompe disease through a potentially groundbreaking treatment.